Clinical Trials Directory

Trials / Completed

CompletedNCT03892213

Pharmacokinetic Drug-Drug Interaction Study

A Phase 1 Pharmacokinetic Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
28 (actual)
Sponsor
Drugs for Neglected Diseases · Academic / Other
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether benznidazole and E1224 should be administered concomitantly in patients with Chagas Disease as not enough data are available. This study aims to assess cross interactions of these two compounds.

Detailed description

Benznidazole and E1224 are intended to be administered concomitantly in patients with Chagas disease. Thus, an in vivo interaction study in healthy volunteers may be justified as the two drugs are intended to be administered concomitantly in patients and no in vivo nor in vitro data are available. In addition both interactions (potential for benznidazole to interact on the pharmacokinetic (PK) of E1224 and potential for E1224 on the PK of benznidazole should be studied. Benznidazole t1/2 is quite short (12 h) whereas E1224 t1/2 is very long (more than 200 h). Therefore it was chosen to study the interaction of E1224 at steady-state while interaction of benznidazole after single dose appears more appropriate instead of a classical randomized cross-over design.

Conditions

Interventions

TypeNameDescription
DRUGBenznidazoleBenznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9\*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12\* until Day 15.
DRUGE1224E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15). On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly.

Timeline

Start date
2014-10-01
Primary completion
2014-12-01
Completion
2015-01-01
First posted
2019-03-27
Last updated
2019-03-27

Locations

1 site across 1 country: Argentina

Source: ClinicalTrials.gov record NCT03892213. Inclusion in this directory is not an endorsement.